Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Gilead Sciences, Inc. (GILD) Insider Trading Activity
Healthcare • Drug Manufacturers - General • 18,000 employees
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Total Value
-$26,642,162.11
Total Shares
3,317,530
Average Trade Value
-$409,879.42
Most Active Insider
Dickinson Andrew D
Total Activity: $93,024,314
Largest Single Transaction
$14,999,996
by Gilead Sciences, Inc. on Feb 18, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
---|---|---|---|---|---|---|
10% Owner
|
Feb 18, 2025 | 1,363,636 | $14,999,996 | 31,424,760 (+4.3%) | Purchase | |
Chief Financial Officer
Officer
|
Feb 18, 2025 | 2,500 | $260,225 | 169,061 (-1.5%) | Sale | |
Chief Financial Officer
Officer
|
Feb 12, 2025 | 18,210 | $1,520,353 | 308,899 (+5.9%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Feb 12, 2025 | 137,676 | $14,073,241 | 171,223 (-80.4%) | Sale | |
Chief Financial Officer
Officer
|
Feb 12, 2025 | 15,600 | $1,259,232 | 290,689 (+5.4%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Feb 12, 2025 | 77,691 | $4,965,232 | 248,914 (+31.2%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Feb 12, 2025 | 26,175 | $1,516,056 | 275,089 (+9.5%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Feb 4, 2025 | 12,371 | $0 | 34,011 (+36.4%) | Grant | |
Chief Commercial Officer
Officer
|
Feb 4, 2025 | 19,793 | $10,000 | 94,933 (+20.8%) | Grant | |
Chief Commercial Officer
Officer
|
Feb 4, 2025 | 45,666 | $4,474,811 | 119,979 (-38.1%) | Payment of Exercise Price | |
Chief Commercial Officer
Officer
|
Feb 4, 2025 | 70,712 | $10,000 | 165,645 (+42.7%) | Grant | |
Chairman CEO
Director, Officer
|
Feb 4, 2025 | 164,473 | $10,000 | 726,032 (+22.7%) | Grant | |
Chairman CEO
Director, Officer
|
Feb 4, 2025 | 60,031 | $10,000 | 561,559 (+10.7%) | Grant | |
Chairman CEO
Director, Officer
|
Feb 4, 2025 | 108,156 | $10,598,206 | 617,876 (-17.5%) | Payment of Exercise Price | |
Chief Financial Officer
Officer
|
Feb 4, 2025 | 43,138 | $4,227,093 | 171,223 (-25.2%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Feb 4, 2025 | 709 | $10,000 | 37,787 (+1.9%) | Grant | |
Chief Financial Officer
Officer
|
Feb 4, 2025 | 64,695 | $10,000 | 214,361 (+30.2%) | Grant | |
Chief Financial Officer
Officer
|
Feb 4, 2025 | 19,793 | $10,000 | 149,666 (+13.2%) | Grant | |
Chief Financial Officer
Officer
|
Jan 31, 2025 | 71,850 | $5,197,629 | 227,893 (+31.5%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Jan 31, 2025 | 26,170 | $1,515,766 | 156,043 (+16.8%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Jan 31, 2025 | 142,180 | $13,822,740 | 129,873 (-109.5%) | Sale | |
Chief Financial Officer
Officer
|
Jan 31, 2025 | 44,160 | $2,887,181 | 273,053 (+16.2%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Jan 25, 2025 | 515 | $0 | 21,827 (+2.4%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Jan 25, 2025 | 187 | $17,404 | 21,640 (-0.9%) | Payment of Exercise Price | |
Chief Financial Officer
Officer
|
Jan 15, 2025 | 2,500 | $228,375 | 129,873 (-1.9%) | Sale | |
10% Owner
|
Dec 18, 2024 | 1,759,978 | $1,830,377 | 9,105,451 (+19.3%) | Purchase | |
Chief Financial Officer
Officer
|
Dec 16, 2024 | 8,500 | $781,660 | 132,373 (-6.4%) | Sale | |
Svp, Controllership
Officer
|
Dec 13, 2024 | 157 | $14,421 | 37,078 (-0.4%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Dec 13, 2024 | 157 | $10,000 | 37,533 (+0.4%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Dec 10, 2024 | 639 | $0 | 21,618 (+3.0%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Dec 10, 2024 | 3,820 | $0 | 84,621 (+4.5%) | Exercise/Conversion | |
Chief Commercial Officer
Officer
|
Dec 10, 2024 | 3,752 | $0 | 76,879 (+4.9%) | Exercise/Conversion | |
Chairman CEO
Director, Officer
|
Dec 10, 2024 | 4,762 | $439,723 | 501,528 (-0.9%) | Payment of Exercise Price | |
Chief Medical Officer
Officer
|
Dec 10, 2024 | 1,771 | $163,534 | 82,850 (-2.1%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Dec 10, 2024 | 408 | $37,675 | 37,078 (-1.1%) | Payment of Exercise Price | |
Chief Commercial Officer
Officer
|
Dec 10, 2024 | 1,739 | $160,579 | 75,140 (-2.3%) | Payment of Exercise Price | |
Svp, Controllership
Officer
|
Dec 10, 2024 | 901 | $0 | 37,486 (+2.4%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Dec 10, 2024 | 306 | $28,256 | 21,312 (-1.4%) | Payment of Exercise Price | |
Chairman CEO
Director, Officer
|
Dec 10, 2024 | 10,295 | $0 | 506,290 (+2.0%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Dec 10, 2024 | 3,640 | $0 | 142,559 (+2.6%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Dec 10, 2024 | 1,686 | $155,685 | 140,873 (-1.2%) | Payment of Exercise Price | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 43,340 | $3,150,818 | 321,604 (+13.5%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 33,660 | $2,314,125 | 217,379 (+15.5%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 120,715 | $11,198,151 | 266,849 (-45.2%) | Sale | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 18,630 | $1,374,335 | 157,549 (+11.8%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 60,885 | $4,378,240 | 278,264 (+21.9%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 127,930 | $11,867,119 | 138,919 (-92.1%) | Sale | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 65,960 | $4,795,292 | 387,564 (+17.0%) | Exercise/Conversion | |
Chief Financial Officer
Officer
|
Nov 29, 2024 | 26,170 | $1,515,766 | 183,719 (+14.2%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 88,119 | $8,106,948 | 99,599 (-88.5%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 10,399 | $956,708 | 80,801 (-12.9%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 57,294 | $5,259,297 | 187,718 (-30.5%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 88,119 | $5,761,220 | 245,012 (+36.0%) | Exercise/Conversion | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 5,200 | $477,381 | 94,399 (-5.5%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 3,199 | $293,679 | 91,200 (-3.5%) | Sale | |
Chief Medical Officer
Officer
|
Nov 27, 2024 | 57,294 | $3,318,468 | 156,893 (+36.5%) | Exercise/Conversion | |
Director
|
Nov 26, 2024 | 5,879 | $359,618 | 11,587 (+50.7%) | Exercise/Conversion | |
Director
|
Nov 26, 2024 | 6,788 | $620,356 | 8,920 (-76.1%) | Sale | |
Director
|
Nov 26, 2024 | 4,121 | $252,823 | 15,708 (+26.2%) | Exercise/Conversion | |
Chief Commercial Officer
Officer
|
Nov 6, 2024 | 5,000 | $456,400 | 73,127 (-6.8%) | Sale | |
Chief Medical Officer
Officer
|
Nov 6, 2024 | 20,590 | $1,883,985 | 104,599 (-19.7%) | Sale | |
Chief Medical Officer
Officer
|
Nov 6, 2024 | 5,000 | $457,500 | 99,599 (-5.0%) | Sale | |
Chief Medical Officer
Officer
|
Nov 6, 2024 | 25,000 | $1,448,000 | 125,189 (+20.0%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Oct 25, 2024 | 514 | $0 | 21,221 (+2.4%) | Exercise/Conversion | |
Evp, Corporate Affairs Gc
Officer
|
Oct 25, 2024 | 242 | $21,538 | 20,979 (-1.2%) | Payment of Exercise Price |